Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0290661 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Yana Sazonova und 6 weiteren Autor:innen. Beteiligte Einrichtung: PEPFAR Coordination Office in Ukraine, Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine. Hauptthemen laut MEDLINE: Substance Abuse, Intravenous, Drug Users, HIV Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: PEPFAR, Alliance for Public Health.
Abstract (Originalsprache)
Achievement of viral load suppression among people living with HIV is one of the most important goals for effective HIV epidemic response. In Ukraine, people who inject drugs (PWID) experience the largest HIV burden. At the same time, this group disproportionally missed out in HIV treatment services. We performed a secondary data analysis of the national-wide cross-sectional bio-behavioral surveillance survey among PWID to assess the population-level prevalence of detectable HIV viremia and identify key characteristics that explain the outcome. Overall, 11.4% of PWID or 52.6% of HIV-positive PWID had a viral load level that exceeded the 1,000 copies/mL threshold. In the group of HIV-positive PWID, the detectable viremia was attributed to younger age, monthly income greater than minimum wage, lower education level, and non-usage of antiretroviral therapy (ART) and opioid agonistic therapy. Compared with HIV-negative PWID, the HIV-positive group with detectable viremia was more likely to be female, represented the middle age group (35–49 years old), had low education and monthly income levels, used opioid drugs, practiced risky injection behavior, and had previous incarceration history. Implementing the HIV case identification and ART linkage interventions focused on the most vulnerable PWID sub-groups might help closing the gaps in ART service coverage and increasing the proportion of HIV-positive PWID with viral load suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- PEPFAR Coordination Office in Ukraine, Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.
- Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.
- State Institution "The L.V. Gromashevskij Institute of Epidemiology and Infectious Diseases of NAMS of Ukraine", Kyiv, Ukraine.
- Monitoring and Evaluation Unit, ICF "Alliance for Public Health", Kyiv, Ukraine.
ORCID-Profile: Yana Sazonova, Tetiana Salyuk, Ezra Barzilay
Förderung
- PEPFAR
- Alliance for Public Health
Zitieren
APA
Sazonova, Y., Kulchynska, R., Azarskova, M., Liulchuk, M., Salyuk, T., Doan, I., & Barzilay, E. (2023). Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions. PLOS ONE. https://doi.org/10.1371/journal.pone.0290661
Vancouver
Sazonova Y, Kulchynska R, Azarskova M, Liulchuk M, Salyuk T, Doan I, et al. Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions. PLOS ONE. 2023. doi:10.1371/journal.pone.0290661
BibTeX
@article{Sazonova2023,
author = {Sazonova, Yana and Kulchynska, Roksolana and Azarskova, Marianna and Liulchuk, Mariia and Salyuk, Tetiana and Doan, Ivan and Barzilay, Ezra},
title = {Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0290661}
}
EUVIMED